Stock Events

Stock Events

Regenicin 

$0.000100
5
+$0.00+0%Tuesday 20:00

Statistics

Day High
0.0001
Day Low
0.0001
52W High
0.7501
52W Low
0.0001
Volume
99,100
Avg. Volume
0
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

Aug 12Expected
Q2 2020
Q4 2020
Q1 2021
Q2 2021
Q4 2021
Q1 2022
Q2 2022
-0
-0
-0
0
Expected EPS
N/A
Actual EPS
-0.0012

Financials

-Profit Margin
Unprofitable
2017
2018
2019
2020
2021
2022
0Revenue
-692,216Net Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap173.95B
Pfizer is involved in biopharmaceuticals, including regenerative medicine, making it a competitor in the broader biotech and healthcare sector.
Novartis
NVS
Mkt Cap303.67B
Novartis focuses on innovative medicines, including those in regenerative medicine, directly competing in the same industry as Regenicin.
Merck
MRK
Mkt Cap368.89B
Merck operates in the pharmaceuticals sector, focusing on innovative treatments that could overlap with Regenicin's regenerative medicine technologies.
Johnson & Johnson
JNJ
Mkt Cap657.68B
Johnson & Johnson, through its subsidiary companies, is involved in the research and development of new healthcare solutions, including regenerative medicine.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences is a biopharmaceutical company that develops medicines in areas of unmet medical need, including regenerative medicine.
AMGEN
AMGN
Mkt Cap251.94B
Amgen is a biotech company focusing on human therapeutics, with interests in regenerative medicine and tissue healing, competing with Regenicin's niche.
Bristol-Myers Squibb
BMY
Mkt Cap127.71B
Bristol Myers Squibb is engaged in the discovery, development, and delivery of medicines, including those in the regenerative medicine space.
Abbvie
ABBV
Mkt Cap521.11B
AbbVie operates in the pharmaceuticals sector, focusing on innovative treatments, including regenerative medicine, which puts it in competition with Regenicin.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG focuses on pharmaceuticals and diagnostics, with a strong emphasis on innovation in medicine, including regenerative therapies.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca is a global, science-led biopharmaceutical business that works in several therapeutic areas, including regenerative medicine, competing with Regenicin's focus.

About

Regenicin, Inc. is dedicated to the development and commercialization of advanced tissue-engineered skin replacement technologies. Its product line features NovaDerm, a sophisticated multi-layered living and cultured skin substitute engineered for treating burn injuries, alongside TempaDerm, which addresses more localized wound areas like ulcers. These innovative solutions aim to rejuvenate the characteristics of healthy human skin, finding application in burn therapy, chronic wound management, and various plastic surgery procedures. Incorporated in 2007 and based in Little Falls, New Jersey, the company was previously known as Windstar, Inc., adopting the Regenicin, Inc. name in July 2010.
Show More
CEO
Randall E. McCoy
Employees
3
Country
United States
ISIN
US75887Q1022

Listings

OTC Link
US
RGIN

0 Comments

Share your thoughts

FAQs

What is Regenicin stock price today?▼
The current price of RGIN is $0.00 USD — it has increased by +0% in the past 24 hours. Watch Regenicin stock price performance more closely on the chart.
What is Regenicin stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Regenicin stocks are traded under the ticker RGIN.
Is Regenicin stock price growing?▼
RGIN stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Regenicin has showed a +0% increase.
What were Regenicin earnings last quarter?▼
RGIN earnings for the last quarter are -0 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Regenicin revenue for the last year?▼
Regenicin revenue for the last year amounts to 0 USD.
What is Regenicin net income for the last year?▼
RGIN net income for the last year is -692,216 USD.
How many employees does Regenicin have?▼
As of November 2, 2026, the company has 3 employees.
In which sector is Regenicin located?▼
Regenicin operates in the Health & Wellness sector.
When did Regenicin complete a stock split?▼
Regenicin has not had any recent stock splits.
Where is Regenicin headquartered?▼
Regenicin is headquartered in Little Falls, United States.